标准风险白血病的异基因外周血干细胞移植。一项多中心试点研究：日本经验。日本血细胞移植研究组。

Allogeneic peripheral blood stem cell transplantation for standard-risk leukemia. A multicenter pilot study: Japanese experience. Japan Blood Cell Transplantation Study Group.

作者信息

Harada M, Shinagawa K, Kawano T, Kasai M, Sawada H, Nakao S, Hyodo H, Aotsuka N, Furukawa T, Hirai H, Eto T, Imai Y, Shimazaki C, Matsue K, Ogawa M, Takaku F

机构信息

Department of Internal Medicine II, Okayama University Medical School, Japan.

出版信息

Bone Marrow Transplant. 1998 Jun;21 Suppl 3:S54-6.

PMID:9712495

Abstract

A multicenter phase II study of allogeneic peripheral blood stem cell transplantation (allo-PBSCT) was conducted. Twenty-two patients (median age, 36 years) with standard-risk leukemia were transplanted with G-CSF-mobilized PBSC from an HLA-identical sibling donor, and received cyclosporine and methotrexate for GVHD prevention. Median days to ANC >500/microl and platelets >50,000/microl were 12 (9-20) and 16 (11-32), respectively. Grade II-IV acute GVHD developed in 6/21 (29%) and extensive chronic GVHD in 12/20 (60%). These observations indicate that allo-PBSCT is characterized by rapid hematologic engraftment, no increase of acute GVHD and an increased risk of chronic GVHD, and can be used as an alternative to allogeneic bone marrow transplantation.

摘要

开展了一项关于异基因外周血干细胞移植（allo-PBSCT）的多中心II期研究。22例标准风险白血病患者（中位年龄36岁）接受了来自人类白细胞抗原（HLA）相合同胞供者经粒细胞集落刺激因子（G-CSF）动员的外周血干细胞移植，并接受环孢素和甲氨蝶呤预防移植物抗宿主病（GVHD）。中性粒细胞绝对计数（ANC）>500/微升和血小板计数>50,000/微升的中位天数分别为12天（9 - 20天）和16天（11 - 32天）。6/21例（29%）发生II - IV级急性GVHD，12/20例（60%）发生广泛慢性GVHD。这些观察结果表明，allo-PBSCT的特点是血液学快速植入，急性GVHD无增加，慢性GVHD风险增加，并且可作为异基因骨髓移植的替代方法。